Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7IA0N
|
|||
| Drug Name |
AMG 757
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 1 | [1] | |
| Small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162.9] | Phase 1 | [2] | ||
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Delta-like protein 3 (DLL3) | Target Info | Inhibitor | [3] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Endocrine resistance | |||
| Notch signaling pathway | ||||
| Th1 and Th2 cell differentiation | ||||
| Pathways in cancer | ||||
| Breast cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04702737) A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of Amgen. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.